1 / 9

antibody drug conjugate

Three major components define an antibody drug conjugate—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. <br>https://www.creative-biolabs.com/adc/services.htm

bellasmith123
Download Presentation

antibody drug conjugate

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antibody Drug Conjugate https://www.creative-biolabs.com/adc/

  2. Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.

  3. ADC mode of action. ADC molecules travel to the tumor site via systematic circulation, bind to tumor surface antigens, and enter the tumor cells via receptor mediated endocytosis (internalization). The payload is released in the cytosol or lysosome to eliminate the cancer cell by disrupting important cellular pathways (microtubule assembly, DNA transcription, mRNA processing…).

  4. ADC molecules travel to the tumor site via systematic circulation, bind to tumor surface antigens, and enter the tumor cells via receptor mediated endocytosis (internalization). The payload is released in the cytosol or lysosome to eliminate the cancer cell by disrupting important cellular pathways (microtubule assembly, DNA transcription, mRNA processing…).

  5. Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.

  6. Designing of an ADC is an elaborate process that involves careful planning, meticulous execution, and intensive trouble-shooting. An effective combination of the most suitable components will greatly increase the chance for a successful ADC.

  7. About • After years of pursuit for perfection, Creative Biolabs has established our leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. Creative Biolabs offers customers with comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation. Furthermore, inventory also contains an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs for quick deployment and concept validation.

  8. Contact • 45-1 Ramsey Road, Shirley, NY 11967, USA • Email: marketing@creative-biolabs.com • www.creative-biolabs.com/car-t

  9. THANK YOU

More Related